- Biotechnology
- Wednesday, 24 Jun 2020
Philogen Received Combination Pack Approval for Nidlegy
Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, on Jan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination of the active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF). NidlegyTM is being developed as a neoadjuvant intralesional treatment for resectable Stage III melanoma patients and in locally advanced, not metastatic nonmelanoma skin cancers. NidlegyTM combination pack has now received confirmation of eligibility to the centralized procedure for submission of an application for a Union Marketing Authorisation under Article 3(1) - Indent 1 - Biotech medicinal product of Regulation (EC) No 726/2004.
"We are extremely pleased to record EMA's agreement to our strategy for the marketing of NidlegyTM as a combination pack that was considered by CHMP 'indispensable for public health reasons,'" commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
Related Industry Updates
Kidney Stones Management Market – Know What Segments & Players Seeking Heavy Attention
Mar 26, 2021
Whole Exome Sequencing Market is expected to reach US$ 153,689.9 Mn by 2027
May 05, 2021
Europe Cannabis Testing Market to See a Huge Rise during 2020-2027 with an improve in Revenue of US$ 807.9Mn| Business Market Insights
Feb 01, 2021
Genetic Testing Services Market is expected to reach US$ 10,556.29 million by 2030
Dec 28, 2023
Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Is Rising With Post COVID-19 Impact Analysis, Development, CAGR , Forecast To 2021-2027
Apr 22, 2021
Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19
Mar 17, 2020
Increasing technological advancements is expected to bolster the gene synthesis market
Aug 31, 2019
Follow us on
